Titration Investigation: Flexible Dosing in Overactive Bladder

Release Date: December 2007
Expiration Date: December 31, 2008

Faculty

Scott A. MacDiarmid, MD Speaker Director, Bladder Control and Pelvic Pain Center Alliance Urology Specialists Greensboro, NC Clinical Faculty, Department of Urology Wake Forest University Winston-Salem, NC

David Staskin, MD Faculty Moderator Associate Professor Departments of Urology New York Presbyterian Hospital New York, NY

Strategies for pharmacological overactive bladder treatment, including the flexible dosing of antimuscarinics, are increasingly determined by assessing the individual patient's severity of symptom bother and the expectations for treatment.

Recent flexible-dosing studies with antimuscarinics suggest that urge urinary and total incontinence may be reduced significantly with a flexible dosing strategy. Dose adjustment may improve therapeutic outcome, facilitating a balance between efficacy and side effects.

This program will examine recent flexible dosing antimuscarinic trials in the treatment of OAB that assess the balance between tolerability and efficacy based on each patient's needs and expectations.

This highly interactive web-based program will create an environment that will promote interaction among the presenters through a combination of brief didactic lectures, panel discussions, and a Q&A session.

This activity will consist of didactic lectures and panel discussions supported by slides posted on the web.

• Read the objectives and other introductory information.
  
• Listen to the audio while viewing the slides; please note that this program was recorded, and as a result, participants will not have the opportunity to ask questions of the presenter.
• Take the post-test.
• Complete the evaluation and registration information.
• Participants who complete the post-test and evaluation will be issued a CME certificate, which may be printed at their location. A database of certificates awarded online is maintained at the Dannemiller Foundation. No additional certificate will be mailed. If you have any questions, you may contact the Dannemiller Foundation at editor@dannemiller.com. Expiration date for credit is December 31, 2008.
• This activity should take about 1 hour to complete.

• Review the dosing options in available antimuscarinic agents and discuss the potential of flexible dosing for control of overactive bladder symptoms
• Assess the balance between safety and tolerability of antimuscarinics to optimize patient outcomes

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Dannemiller Memorial Educational Foundation and The Customer Link, Inc. The Dannemiller Memorial Educational Foundation is accredited by the ACCME to provide continuing medical education for physicians.

The Dannemiller Memorial Educational Foundation designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity is designed for urologists and primary care physicians with a special interest in urology.

In accordance with the Accreditation Council for Continuing Medication Education (ACCME), the Dannemiller Memorial Educational Foundation requires that any person who is in a position to control the content of a CME activity must disclose all relevant financial relationships they have with a commercial interest. Accordingly:

Dr. MacDiarmid reports that he serves as a consultant for Pfizer Inc.; Watson Pharmaceuticals, Inc. and Esprit Pharma. He also serves as a speaker for Pfizer Inc.; Watson Pharmaceuticals, Inc, Ortho-McNeil-Janessen Pharmaceuticals, Inc.; Novartis AG, Astellas Pharma us, Inc; and Esprit Pharma, Inc.

Dr. Staskin reported that he serves as a consultant and speaker for Astellas Pharma US, Inc.; Esprit Pharma; Pfizer, Inc.; and Watson Pharmaceuticals, Inc. He also receives grant/research support from Esprit Pharma, Inc. and Watson Pharmaceuticals, Inc.

Elke Graser, medical writer, has no financial relationships with any commercial interests that are relevant to this activity to disclose.

The Dannemiller Memorial Educational Foundation staff that was involved in the development of this activity have no financial relationships with any commercial interests that are relevant to this activity. All staff of The Customer Link, Inc. involved in the development of this activity have no financial relationships to disclose.

To resolve identified conflicts of interest, the educational content was fully peer-reviewed by a physician member of the Dannemiller Clinical Content Review Committee who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence-based, and commercially balanced.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the Dannemiller Memorial Educational Foundation, Astellas Pharma US, Inc.; or The Customer Link, Inc. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.